

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

# Soleus muscle size and function: A surrogate measure of health status in human heart failure?

Daniel J. Green<sup>1,2</sup>, Fausto A. Panizzolo<sup>1</sup>, David G. Lloyd<sup>1,3</sup>, Jonas Rubenson<sup>1,4</sup>,  
Andrew J. Maiorana<sup>5,6,7</sup>

<sup>1</sup> *The School of Sport Science, Exercise and Health,*  
The University of Western Australia, Crawley, WA, 6009, Australia

<sup>2</sup> *Research Institute for Sport and Exercise Science,*  
Liverpool John Moores University, Liverpool, United Kingdom

<sup>3</sup> *Centre for Musculoskeletal Research,*  
Menzies Health Institute Queensland

<sup>4</sup> *Biomechanics Laboratory, Department of Kinesiology,*  
Pennsylvania State University, University Park, PA, 16802, USA

<sup>5</sup> *Advanced Heart Failure and Cardiac Transplant Service,*  
Royal Perth Hospital, Perth, WA 6000, Australia

<sup>6</sup> *School of Physiotherapy and Exercise Science,*  
Curtin University, Perth, WA 6102, Australia

<sup>7</sup> *Allied Health Department,*  
Fiona Stanley Hospital, Murdoch, 6150 WA, Australia

Author for correspondence:  
Winthrop Professor Daniel J. Green  
The School of Sport Science, Exercise and Health, The University of Western Australia, Crawley,  
WA, 6009, Australia. Tel: + 61 8 6488 5533, Email: danny.green@uwa.edu.au

**SHORT TITLE:** Skeletal muscle in chronic heart failure

**DISCLOSURE AND CONFLICT OF INTEREST:** No conflicts of interest, financial or  
otherwise, are declared by the authors.

## GRANTS

This work was supported by a Grant-in-Aid (G09P 4469) from the National Heart Foundation of  
Australia to J.R., D.J.G., A.J.M. and D.G.L. and a thesis dissertation grant from the International  
Society of Biomechanics to F.A.P.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**ABSTRACT**

We propose the hypothesis that soleus muscle function may provide a surrogate measure of functional capacity in patients with heart failure. We summarize literature pertaining to skeletal muscle as a locus of fatigue and present our recent findings, utilising *in vivo* imaging in combination with biomechanical experimentation and modelling, to reveal novel structure-function relationships in CHF skeletal muscle and gait.

**SUMMARY**

We propose the novel hypothesis that soleus muscle function may provide a valid surrogate measure of functional capacity and health status in patients with chronic heart failure.

**KEYWORDS:** active force, passive force, strength, skeletal muscle, heart failure, exercise training

## INTRODUCTION

### A BRIEF HISTORY OF EXERCISE AND SKELETAL MUSCLE FUNCTION IN CHRONIC HEART FAILURE MANAGEMENT

The 11th edition of Harrison's Textbook of Internal Medicine, published in 1987, stated that treatment of heart failure should *"consist of reducing physical activity, instituting rest and reducing afterload."* By the early 2000's, the American Heart Association concluded that exercise training in chronic heart failure (CHF) was *"safe and beneficial overall in improving peak  $\dot{V}O_2$ , peak workload, exercise duration, and parameters of submaximal exercise performance. In addition, quality of life improves...."* (28). This statement led other peak bodies to produce recommendations such as: *"When medically stable, all CHF patients should be considered for referral to an exercise program"* (23).

The narrative underlying this paradigm shift is an exemplar of translational research in exercise science, with ultimate global impact on patient management. The story has several starting points, including: recognition of the importance of peak oxygen uptake ( $\dot{V}O_2$  peak) as an index of systemic and integrated physiological function that outperforms traditional indices used in prognostication and transplant stratification (20), identification of skeletal muscle as an important locus of exercise intolerance in heart failure (8), courageous early exercise-training studies illustrating the reversibility of such limitations (32), ambitious studies indicating that training could induce improvement in outcomes (2) and establishment of the hemodynamic safety of well controlled and targeted exercise interventions (3). There are also early examples, in the context of the exercise training literature, of patient-centred individualisation of prescription utilising novel and targeted interventional approaches (16,18), a trend that is only now emerging as a mainstream agenda (10).

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

In this brief paper, we revisit and acknowledge the important contributions made by studies that indicated that peripheral limitations to performance are amenable to modification in CHF (10). We also present some recent findings using contemporary techniques for the study of skeletal muscle function *in vivo* to pose the questions: 1. Is it the quantity or the quality of skeletal muscle that matters in CHF? 2. Can soleus muscle function serve as a surrogate for global functional capacity in CHF? 3. What are the implications for the design of future exercise interventions?

**THE ONGOING BURDEN OF HUMAN CHRONIC HEART FAILURE**

Chronic heart failure continues to be a major global health burden. Two million new cases of heart failure are diagnosed worldwide every year, for an estimated total of 22 million affected. In the US, recent data indicate that 5.1 million people are affected by CHF and it is one of the most common reasons for hospital admission and general practitioner consultations in the elderly. Despite some improvement across recent decades, the mortality rates associated with CHF remain very high, with a reported risk-adjusted 1-year mortality of 29.6% in 2008 in the US (4).

**CLINICAL RELEVANCE OF THE LOCUS OF FATIGUE IN CHRONIC HEART FAILURE**

Poor exercise tolerance is a cardinal symptom of CHF, which significantly impacts upon quality of life and the capacity to perform tasks of daily living (6,9). Peak oxygen uptake outperforms ejection fraction and hemodynamic indices in terms of prognostication (20) and is used to guide transplantation and ventricular assist device implantation (20,21).

Research over the past two decades has identified an intriguing paradox in CHF, in that the primary locus of exercise intolerance often lies in the skeletal muscle, rather than the heart itself (7,27). Aerobic capacity and resting cardiac function are poorly correlated in patients with CHF (9).

1  
2 Instead, peripheral factors including impaired blood flow (18) and skeletal muscle dysfunction (6)  
3 have a greater bearing on aerobic capacity and are intrinsically linked to the exercise intolerance in  
4 this condition.  
5  
6

7  
8  
9 Recognition of the importance of peripheral abnormalities in CHF led to the “skeletal muscle  
10 hypothesis” (6), which proposes that activation of muscle ergoreceptors (receptors activated during  
11 muscle contractions that mediate physiologic adjustments) generate symptoms during exercise and  
12 that muscle wasting contributes to a wicked cycle of reflex neuro-hormonal activation, peripheral  
13 vasoconstriction, disease progression and physical inactivity (Figure 1). Consistent with the muscle  
14 hypothesis, muscle wasting is strongly correlated with reduced aerobic capacity (5) and poor  
15 prognosis (1). A recent analysis of 200 CHF patients revealed that reduced muscle mass is  
16 independently associated with lower absolute  $\dot{V}O_2$  peak ( $\text{ml}\cdot\text{min}^{-1}$ ) when age, sex, ejection fraction  
17 and co-morbidities were accounted for, and that muscle mass is directly linked to disease  
18 progression (12). These findings place skeletal muscle function at center-stage when exercise-based  
19 strategies are devised to target functional limitation in a large proportion of patients with stable  
20 CHF.  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

## 41 **SKELETAL MUSCLE ARCHITECTURE AND MECHANICS IN HUMAN CHRONIC** 42 43 **HEART FAILURE**

44  
45 Muscle architecture is closely linked to *in vivo* muscle mechanics. Muscle volume is one of the  
46 primary determinants of the muscle’s capacity to generate mechanical work. Maximal muscle force,  
47 and thus also joint torque production is, on the other hand, more closely associated with muscle  
48 physiological cross sectional area (PCSA) (30). PCSA is determined by muscle volume, as well as  
49 fibre length and pennation angle (26). Whilst some studies have examined muscle size in context of  
50 strength and functional limitations in CHF (13), few have investigated detailed architectural  
51 parameters.  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61

1  
2 In addition, two mechanical properties that influence *in vivo* muscle mechanics independently of  
3  
4 muscle volume and PCSA are its fiber operating lengths and velocities (force-length and force-  
5  
6 velocity properties). To the best of our knowledge no previous studies have examined fiber length  
7  
8 and velocity characteristics of skeletal muscle in CHF. It is widely accepted that muscles operating  
9  
10 outside their optimal length and velocity ranges are severely restricted in their ability to produce  
11  
12 force, work and power, resulting in loss of function (30). The capacity of muscle to generate  
13  
14 mechanical work is optimal when it functions over the plateau region of the force-length curve.  
15  
16 When skeletal muscle operates outside this range (e.g. if muscle fiber lengths are reduced),  
17  
18 mechanical work and power are drastically compromised. Although abnormalities in CHF skeletal  
19  
20 muscle structure such as atrophy and a shift to type II fibers (6) and decreased cross-bridge kinetics  
21  
22 (22) make them susceptible to sub-optimal function, muscle architecture and mechanics as a  
23  
24 limitation to skeletal muscle function have not previously been studied in CHF.  
25  
26  
27  
28  
29  
30  
31  
32  
33

## 34 **RECENT STUDIES RELATING PLANTARFLEXOR MUSCLE MORPHOLOGY AND** 35 36 **FUNCTION TO EXERCISE CAPACITY IN CHRONIC HEART FAILURE**

37  
38 We recently reported alterations on the functional and morphological properties of the plantarflexor  
39  
40 muscles in patients affected by CHF (NYHA Class II–IV; ejection fraction  $< 40 \pm 10\%$ ; age  $62 \pm 10$   
41  
42 yr; mean  $\pm$  SD) (26), relative to control participants matched for age, sex, adiposity and physical  
43  
44 activity levels. These studies are based on detailed measurements of muscle architecture using state-  
45  
46 of-the art 3D ultrasound imaging (dynamic B-mode imaging coupled with simultaneous motion  
47  
48 capture of the probe) and estimates of active and passive muscle loads from a novel framework  
49  
50 incorporating empirical data (dynamic muscle fascicle imaging, electromyography and  
51  
52 dynamometry) and musculoskeletal modeling. In an effort to maximize accuracy, the derived  
53  
54 estimates of muscle loads took into account agonist and antagonist muscle actions, muscle-tendon  
55  
56 dynamics and subject-specific muscle moment arm data (Figure 2).  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2 Despite a similar overall lower limb lean mass, CHF patients exhibited ~25% lower combined  
3  
4 triceps surae volume (Fig. 3a) and physiological cross-sectional area (PCSA) (25). These reductions  
5  
6 in triceps surae size were explained primarily by the marked reductions in the soleus (SOL). A  
7  
8 strong correlation ( $r = 0.93$ ) was observed between absolute triceps surae volume and  $\dot{V}O_2$  peak in  
9  
10 CHF patients but not control participants. Furthermore, body mass-specific SOL volume, unlike the  
11  
12 other triceps surae muscles, correlated strongly with body mass-specific  $\dot{V}O_2$  peak in CHF (Figure  
13  
14 3b). The SOL is a key locomotor and postural muscle in humans and these data, together with a  
15  
16 strong correlation between body mass-normalized plantarflexor strength and mass-specific  $\dot{V}O_2$   
17  
18 peak in CHF patients (26), raise the possibility that the SOL may be a sentinel skeletal muscle in  
19  
20 terms of identifying the severity of functional impairment in CHF.  
21  
22  
23  
24  
25  
26  
27  
28

29 These findings were corroborated (24) by observation that the smaller SOL of CHF patients  
30  
31 generated lower absolute voluntary active and passive forces (at equivalent levels of passive strain),  
32  
33 compared to healthy individuals (Figure 4). Importantly, however, this difference was not present  
34  
35 when the data were normalized by muscle cross-sectional area or volume (Figure 4), nor were the  
36  
37 normalized active or passive force-length curves different (normalized to optimal fascicle lengths).  
38  
39 This detailed single muscle analysis suggested to us that the reduced muscle force in CHF may be  
40  
41 more strongly associated with muscle size than muscle structural, mechanical or bioenergetic  
42  
43 properties.  
44  
45  
46  
47  
48  
49  
50

51 Similar findings were observed for the SOL muscle when subjects performed isokinetic  
52  
53 contractions over the functional ankle range of motion, suggesting a reduction of the total amount of  
54  
55 mechanical work generated by the muscle fibers in CHF (Figure 5a). Nevertheless, isokinetic  
56  
57 experiments revealed that the ability of the SOL muscle to produce mechanical work is not  
58  
59 compromised in CHF when the data were normalized by muscle volume (Figure 5b).  
60  
61  
62  
63  
64  
65

1  
2 Notwithstanding the findings outlined above, which tend to implicate SOL muscle size rather than  
3  
4 intrinsic muscle functional “quality” as a limitation in CHF, we observed some evidence of altered  
5  
6 muscle properties in CHF patients. The CHF group exhibited ~20% ( $p < 0.05$ ) shorter optimal  
7  
8 fascicle lengths (i.e. the length where peak voluntary isometric force was achieved) as well as  
9  
10 shorter passive fascicle lengths, compared to the age-matched control group (24). The shorter  
11  
12 passive fascicle lengths resulted in higher passive force for a given absolute muscle length. It is  
13  
14 possible that shorter fascicle lengths result in the muscle operating at longer lengths compared to  
15  
16 that of healthy individuals during functional tasks such as walking. This could, in turn, result in  
17  
18 altered force-length-velocity characteristics of the muscle that lead to a reduced force and work  
19  
20 capacity. Conversely, a shorter optimal fascicle length in CHF might accommodate a more  
21  
22 compliant Achilles tendon in CHF; which in turn may result from a smaller tendon cross-sectional  
23  
24 area (26). While the precise mechanisms underlying these characteristics have not been defined,  
25  
26 they probably reflect a complex interplay between neurohumoral activation, impaired peripheral  
27  
28 blood flow and reduced activity levels. For example, impaired peripheral blood flow in CHF may  
29  
30 have a more pronounced effect on distal compared with proximal limb muscles, while the greater  
31  
32 reduction in SOL muscle volume compared with the medial gastrocnemius may reflect the relative  
33  
34 contribution to mechanical work among the lower limb muscles during walking (25). This is an  
35  
36 intriguing area which requires further detailed experimentation.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

48 The morphological and functional abnormalities we report above, particularly in the plantarflexors  
49  
50 and SOL, could provide a harbinger of impaired function and fatigue early in the clinical course in  
51  
52 CHF. In another recent study (25) we compared the mechanics of walking in CHF with that of  
53  
54 healthy matched population. Minimal difference in preferred speed or overall joint kinematics and  
55  
56 kinetics were observed between groups, a finding that may possibly be explained by optimization of  
57  
58 the mechanical cost of transport (i.e. the amount of mechanical work performed per distance  
59  
60  
61  
62  
63  
64  
65



1 traveled;  $J.kg^{-1}.m^{-1}$ ). Nevertheless, when normalized to triceps surae volume, a 2-fold increase in  
2 ankle plantarflexion work was required in CHF. This, together with a greater reliance on the ankle  
3  
4 to power walking in CHF patients, may contribute to the mechanisms underlying reduced exercise  
5  
6 capacity and marked fatigability in CHF.  
7  
8  
9

10  
11 An important caveat related to the studies described above is that they were undertaken in patients  
12  
13 with heart failure associated with impaired ejection fraction. Further studies are required to establish  
14  
15 whether a similar relationship exists between aerobic capacity and soleus function in patients with  
16  
17 heart failure and preserved ejection fraction.  
18  
19  
20  
21

## 22 **IMPLICATIONS FOR DESIGN OF EXERCISE INTERVENTIONS**

23  
24 Studies of exercise training have established that the skeletal muscle limitations to function are  
25  
26 amenable to improvement (7,15,16,18) and that exercise training improves functional capacity,  
27  
28 cardiovascular mortality (33), hospitalizations (11) and quality of life (36). These benefits typically  
29  
30 occur in the absence of changes in cardiac function (2,27). The HF-Action trial, which randomised  
31  
32 2331 heart failure subjects (NYHA II-IV, EF<35%), indicated that, after adjustment for prognostic  
33  
34 factors, exercise training was associated with a 15% decrease in cardiovascular mortality/CHF  
35  
36 hospitalizations. It was concluded that *“The HF-ACTION study supports a structured exercise  
37  
38 training program for patients with reduced LV function and HF symptoms in addition to evidence-  
39  
40 based therapy”* (33). However, few attempts have been made to address the question of which  
41  
42 exercise prescription will optimise outcomes in HF. Commentary relating to the HF-ACTION trial  
43  
44 included *“The one thing this trial does not show is what type of exercise to advocate”* (33).  
45  
46  
47  
48  
49  
50  
51  
52

53  
54 Logically, interventions that present the muscle with an intense stimulus, whilst minimizing  
55  
56 cardiovascular burden, have the potential to amplify functional gains whilst minimizing acute  
57  
58 exercise risk. In accordance with this theoretical framework, we developed in the 1990’s  
59  
60  
61

1 individually tailored circuit weight training (CWT) programs focusing on isolated muscle groups  
2 and based on comprehensive *a priori* exercise testing (16,18). Because the exercises were  
3  
4 performed on isolated muscle groups at any one time, the intensity of effort was relatively high,  
5  
6 whilst the cardiovascular burden was modest (3,14). We also successfully established the  
7  
8 physiological benefits of such programs in other clinical conditions in a series of experiments  
9  
10 (17,34,35). These studies were among the first to utilize resistance modalities in CHF and they  
11  
12 directly informed the development of new exercise strategies which are now recognized  
13  
14 internationally (28). This work has also directly translated into changes in the management of CHF  
15  
16 in Australia and elsewhere (31).  
17  
18  
19  
20  
21  
22  
23

24 Despite advances in knowledge and clinical practice which have resulted from the development of  
25  
26 individually-tailored exercise interventions aimed at reversing physiological limitations in CHF, no  
27  
28 previous study has specifically devised exercise training programs based on ameliorating deficits in  
29  
30 muscle mechanics (e.g. muscle architecture including muscle length, and mechanical force and  
31  
32 work capacities). This is surprising, given the accepted importance in CHF of abnormalities in  
33  
34 length tension relationships of cardiac myocytes (i.e. Frank-Starling impacts) and also because of  
35  
36 the proven benefits of training interventions focussed on improving muscle mechanics in subjects  
37  
38 with other forms of skeletal myopathies (29). The questions that now emerge, include “How can  
39  
40 exercise training interventions that specifically target limitations in muscle mechanics be designed  
41  
42 for large cohorts of patients, in a manner that is time efficient, tolerable and effective?” This is a  
43  
44 future challenge for researchers in the domain of clinical cardiovascular exercise science.  
45  
46  
47  
48  
49  
50  
51  
52

### 53 **IMPLICATIONS FOR CLINICAL SURVEILLANCE**

54  
55 Cardiorespiratory fitness (VO<sub>2</sub>peak testing) is routinely assessed in patients with CHF due to its  
56  
57 strong prognostic value (19). Such tests are expensive and require a high degree of operator  
58  
59 expertise and training. The close relationship observed between soleus muscle function and aerobic  
60  
61

1 capacity in patients with CHF makes a case for the serial assessment of soleus muscle function for  
2 monitoring changes in clinical status over time. While the studies cited in this review have  
3 employed isokinetic dynamometry, protocols to assess soleus muscle strength and endurance that  
4 utilise resistance exercise equipment routinely available in cardiac rehabilitation programs could  
5 quite easily be developed. Similarly, we have developed non-invasive ultrasound-based approaches  
6 to the quantification of the volume of the triceps surae (26) which are cheap and suitable for use in  
7 patients with implanted devices, who are MRI contraindicated. Such assessments would logically  
8 be conducted by exercise specialists, with results conveyed to medical staff to support clinical  
9 surveillance. The degree to which changes in soleus and other skeletal muscle size and function  
10 relate to, or predict, changes in clinical status should form the basis of future research to test and  
11 refine such protocols.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## SUMMARY

1  
2 Skeletal muscle function is an important locus of fatigue in heart failure, with clinical implications  
3  
4 related to survival, stratification for transplant and ventricular assist device implantation. In order  
5  
6 to optimise exercise training for subjects with chronic heart failure, the limitations to performance  
7  
8 must first be fully understood. Taken together, our recent studies of the skeletal muscle mechanics  
9  
10 of patients with CHF suggest that abnormalities in the triceps surae. In particular the SOL appears  
11  
12 to be particularly susceptible to the muscle wasting and impaired aerobic capacity which  
13  
14 characterize CHF. They also highlight a link between the morphological and functional alterations  
15  
16 of the calf muscles and fatigue experienced during walking in CHF. Our recent integrated muscle-  
17  
18 level and functional gait analyses indicate that reversing these limitations may depend foremost on  
19  
20 restoring muscle size, although muscle ‘quality’ (in particular muscle length) may play a further  
21  
22 important role. Abnormalities in soleus muscle volume and quality may provide a sentinel for  
23  
24 detection of early decompensation and a target for specifically designed interventional strategies,  
25  
26 although further work is required to develop 3D ultrasound approaches. It is conceivable that, in  
27  
28 time, assessment of triceps surae volume and quality will become more feasible\ and cheaper with  
29  
30 less user dependence. We hope that this brief review raises useful hypotheses for future studies  
31  
32 aimed at individualised detection of disease progression and the earliest and most effective  
33  
34 rehabilitative intervention.  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## References

- 1 Anker SD, Ponikowski P, Varney S, et al. Wasting as an independent risk factor for mortality in chronic heart failure. *Lancet*. 1997;349:1050-3.
- 2 Belardinelli R, Georgiou D, Cianci G, Purcaro A. Randomized, controlled trial of long-term moderate exercise training in chronic heart failure: Effects on functional capacity, quality of life, and clinical outcome. *Circulation*. 1999;99:1173-82.
- 3 Cheetham C, Green D, Collis J, Dembo L, O'Driscoll G. Effect of aerobic and resistance exercise on central hemodynamic responses in severe chronic heart failure. *J Appl Physiol* 2002;93:175-80.
- 4 Chen J, Normand SL, Wang Y, Krumholz HM. National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries. *JAMA*. 1998;306:1669-78.
- 5 Cicoira M, Zanolla L, Franceschini L, et al. Skeletal muscle mass independently predicts peak oxygen consumption and ventilatory response during exercise in noncachectic patients with chronic heart failure. *J Am Coll Cardiol*. 2001;37:2080-5.
- 6 Clark AL, Poole-Wilson PA, Coats AJ. Exercise limitation in chronic heart failure: central role of the periphery. *J Am Coll Cardiol*. 1996;28:1092-102.
- 7 Coats AJS, Adamopoulos S, Radaelli A, et al. Controlled trial of physical training in chronic heart failure: Exercise performance, hemodynamics, ventilation, and autonomic function. *Circulation* 1992;85:2119-31.
- 8 Coats AJS, Clark AL, Piepoli M, Volterrani M, Poole-Wilson PA. Symptoms and quality of life in heart failure: The muscle hypothesis. *Br Heart J* 1994;72:36-9.
- 9 Cohn JN, Johnson GR, Shabetai R, et al. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. *Circulation* 1993;87:5-16.
- 10 DeMaeyer C, Beckers P, Vrints CJ, Conraads VM. Exercise training in chronic heart failure. *Ther Adv Chronic Dis* 2013;4:105-17.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65
- 11 Elahi M, Mahmood M, Shahbaz A, et al. Current concepts underlying benefits of exercise training in congestive heart failure patients. *Curr Cardiol Rev* 2010;6:104-11.
  - 12 Fülster S, Tacke M, Sandek A, et al. Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF). *Eur Heart J*. 2013;34:512-9.
  - 13 Gosker HR, Wouters EF, van der Vusse GJ, Schols AM. Skeletal muscle dysfunction in chronic obstructive pulmonary disease and chronic heart failure: underlying mechanisms and therapy perspectives. *Am J Clin Nutr*. 2000;71:1033-47.
  - 14 Green DJ, Watts K, Maiorana AJ, O'Driscoll JG. A comparison of ambulatory oxygen consumption during circuit training and aerobic exercise in patients with chronic heart failure. *J Cardiopulm Rehab* 2001;21:167-74.
  - 15 Hambrecht R, Fiehn E, Weigl C, et al. Regular physical exercise corrects endothelial dysfunction and improves exercise capacity in patients with chronic heart failure. *Circulation* 1998;98:2709-15.
  - 16 Maiorana A, O'Driscoll G, Cheetham C, et al. Combined aerobic and resistance exercise training improves functional capacity and strength in CHF. *J Appl Physiol*. 2000;88:1565-70.
  - 17 Maiorana A, O'Driscoll G, Cheetham C, et al. The effect of combined aerobic and resistance exercise training on vascular function in type 2 diabetes. *J Am Coll Cardiol*. 2001;38:860-6.
  - 18 Maiorana A, O'Driscoll G, Dembo L, et al. Effect of aerobic and resistance exercise training on vascular function in heart failure. *Am J Physiol - Hear Circ Physiol* 2000;279:1999-2005.
  - 19 Mancini D, LeJemtel T, Aaronson K. Peak VO<sub>2</sub>: a simple yet enduring standard. *Circulation*. 2000;101:1080-2.
  - 20 Mancini DM, Eisen H, Kussmaul W, Mull R, Edmonds LH, Wilson JR. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. *Circulation*. 1991;83:778-86.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65
- 21 Mehra MR, Kobashigawa J, Starling R, et al. Listing criteria for heart transplantation: international society for heart and lung transplantation guidelines for the care of cardiac transplant candidates *J Heart Lung Transpl.* 2006;25:1024-42.
- 22 Miller MS, VanBuren P, LeWinter MM, et al. Chronic heart failure decreases cross-bridge kinetics in single skeletal muscle fibres from humans. *J Physiol.* 2010;588:4039-53.
- 23 National. Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand. Guidelines for the prevention, detection and management of chronic heart failure in Australia. 2011.
- 24 Panizzolo FA, Maiorana A, Naylor LH, et al. Passive and active soleus muscle forces in chronic heart failure in heart failure. *Int Soc of Biomechanics XXV Glasgow.* 2015.
- 25 Panizzolo FA, Maiorana AJ, Naylor LH, et al. Gait analysis in chronic heart failure: The calf as a locus of impaired walking capacity. *J Biomech.* 2014;47:3719-25.
- 26 Panizzolo FA, Maiorana AJ, Naylor LH, et al. Is the soleus a sentinel muscle for impaired aerobic capacity in heart failure? *Med Sci Sports Exerc.* 2015;47:498-508.
- 27 Piepoli MF, Davos C, Francis DP, Coats AJ. ExTraMATCH Collaborative. Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH). *Br Med J.* 2004;328:189-92.
- 28 Pina IL, Apstein CS, Balady GJ, et al. Exercise and Heart Failure: A statement from the American Heart Association Committee on exercise, rehabilitation, and prevention. *Circulation.* 2003;107:1210-25.
- 29 Roig M, Shadgan B, Reid WD. Eccentric exercise in patients with chronic health conditions: a systematic review. *Physiother Can* 2008;60:146-60.
- 30 Rubenson J, Pires NJ, Loi H, Pinniger GJ, Shannon DG. On the ascent: the soleus operating length is conserved to the ascending limb of the force-length curve across gait mechanics in humans. *J Exp Biol.* 2012;215:3539-51.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

31 Selig SE, Levinger I, Williams AD, et al. Exercise & Sports Science Australia Position Statement on exercise training and chronic heart failure. *J Sci Med Sport*. 2010;13:288-94.

32 Sullivan MJ, Higginbotham MB, Cobb FR. Exercise training in patients with severe left ventricular dysfunction. Hemodynamic and metabolic effects. *Circulation*. 1988;78:506-15.

33 TheHeart.org. HF-ACTION misses , but experts say results support intensive exercise in HF patients. <http://www.theheart.org/article/printdo?primaryKey=919703>. 2008.

34 Walsh JH, Bilsborough W, Maiorana A, et al. Exercise training improves conduit vessel function in patients with coronary artery disease. *J Appl Physiol*. 2003;95:20-5.

35 Walsh JH, Yong G, Cheetham C, et al. Effects of exercise training on conduit and resistance vessel function in treated and untreated hypercholesterolaemic subjects. *Eur Heart J* 2003;24:1681-9.

36 Willenheimer RE. Exercise training in heart failure improves quality of life and exercise capacity. *Eur Heart J* 1998;19:774-81.



## Figure captions

1  
2  
3  
4 **Figure 1.** Model depicting the impact of peripheral limitations in chronic heart failure (CHF) based  
5  
6 on (6). Abnormalities in skeletal muscle limit exercise capacity and exacerbate  
7  
8 symptoms. Personalized exercise prescription is proposed as a means to reverse the  
9  
10 progression of the disease by acting on three different pathways influencing skeletal  
11  
12 muscle health, namely the muscles' morphological and architectural properties, their  
13  
14 mechanical properties, and their functional characteristics during movement.  
15  
16  
17  
18  
19  
20

21 **Figure 2.** Schematic showing analytical framework for assessing skeletal muscle morphology,  
22  
23 mechanical properties and function including experimental and modeling approaches.  
24  
25 Active and passive joint torque and joint range of motion assessed by dynamometry **(a)**.  
26  
27 B-mode ultrasound techniques to assess muscle fascicle lengths and pennation angles  
28  
29 dynamically (image depicts the soleus muscle) **(b)**; three-dimensional architecture  
30  
31 including individual muscle volume and physiological cross-sectional area (image depicts  
32  
33 the individual muscles of the triceps surae) **(c)**; and tendon moment arms using a  
34  
35 combination of muscle imaging and optical tracking of joint centers **(d)**. Surface  
36  
37 electromyography to assess muscle excitation and activation of agonist and antagonist  
38  
39 muscles **(e)**. Experimental data **(a-e)** form the basis for subject-specific musculoskeletal  
40  
41 models (OpenSim) **(f)** that permit further assessment of muscle properties and function  
42  
43 including estimates of individual peak active muscle force and passive muscle force.  
44  
45  
46  
47  
48  
49  
50  
51  
52

53 **Figure 3.** Triceps surae volume **(a)** and relationship between SOL muscle volume and aerobic  
54  
55 capacity **(b)**. The chronic heart failure (CHF) group is displayed in grey the control  
56  
57 group in black; \* designates a significant difference ( $p < 0.05$ ) between the CHF and the  
58  
59 control group.  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**Figure 4.** Absolute peak voluntary force production **(a)** and normalized absolute peak voluntary force production **(b)**. The chronic heart failure (CHF) group is displayed in grey bars, and the control group in black bars. Data are means  $\pm$  S.D.; \* designates a significant difference ( $p < 0.05$ ) between the CHF and the control group.

**Figure 5.** Work produced by the plantarflexors **(a)** and work produced by the plantarflexors normalized by SOL muscle volume obtained in isokinetic condition ( $5^\circ/s$ ) **(b)**. The chronic heart failure (CHF) group is displayed in grey bars, and the control group in black bars. Data are means  $\pm$  S.D.

Figure 1 tiff






Figure 2 tiff



(a)



(b)

